Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AB Science    AB   FR0010557264

AB SCIENCE

(AB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
10.42(c) 10.2(c) 10.5(c) 10.44(c) 10.3(c) Last
137 279 88 545 185 651 460 074 140 036 Volume
+1.17% -2.11% +2.94% -0.57% -1.34% Change
More quotes
Financials
Sales 2020 1,80 M 2,12 M 2,12 M
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Sales 2021 2,00 M 2,36 M 2,36 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 462 M 546 M 544 M
Capi. / Sales 2020 256x
Capi. / Sales 2021 231x
Nbr of Employees 93
Free-Float 55,3%
More Financials
Company
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals. 
Sector
Pharmaceuticals
Calendar
05/03Earnings Release
More about the company
All news about AB SCIENCE
10/20AB SCIENCE : announces positive top-line Phase 3 results for oral masitinib in s..
AQ
10/20AB SCIENCE : announces positive top-line Phase 3 results for oral masitinib in s..
AQ
10/20SCIENCE : AB Science announces positive top-line Phase 3 results for oral masiti..
GL
10/20AB Science announces positive top-line Phase 3 results for oral masitinib in ..
GL
10/13SCIENCE : AB Science announces that results from masitinib study AB07015 in seve..
GL
10/13AB SCIENCE : announces that results from masitinib study AB07015 in severe asthm..
AQ
10/13AB SCIENCE : announces that results from masitinib study AB07015 in severe asthm..
AQ
10/13AB Science announces that results from masitinib study AB07015 in severe asth..
GL
09/30SCIENCE : 2020 Half-year Financial Report (english version)
PU
09/30AB SCIENCE : today reports its revenues for the first half of 2020
AQ
09/30SCIENCE : AB Science today reports its revenues for the first half of 2020
GL
09/30AB Science today reports its revenues for the first half of 2020
GL
09/30AB SCIENCE : today reports its revenues for the first half of 2020
AQ
09/30AB SCIENCE : Half-year results
CO
09/14SCIENCE : Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at..
PU
More news
News in other languages on AB SCIENCE
10/21AB SCIENCE : parmi les plus fortes hausses du SRD à la mi-séance du mercredi 21 ..
10/21EN DIRECT DES MARCHES : Vivendi, Vinci, Nestlé, Iberdrola, Ericsson, Netflix, Sn..
10/20SCIENCE : AB Science annonce des résultats positifs de Phase 3 du masitinib dans..
10/14AB SCIENCE : soutenu par le potentiel du masitinib dans l'asthme sévère
10/14Les valeurs à suivre aujourd'hui à Paris Mercredi 14 octobre 2020
More news
Chart AB SCIENCE
Duration : Period :
AB Science Technical Analysis Chart | AB | FR0010557264 | MarketScreener
Technical analysis trends AB SCIENCE
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 11,50 €
Last Close Price 10,30 €
Spread / Highest target 26,2%
Spread / Average Target 11,7%
Spread / Lowest Target -2,91%
Managers
NameTitle
Alain Moussy Chairman, CEO & Scientific Director
Laurent Guy Chief Financial Officer
Antonello Cervone Director-Information Technology
Catherine Marle Head-Clinical Operations
Jean-Pierre Kinet Director
Sector and Competitors
1st jan.Capitalization (M$)
AB SCIENCE91.45%555
MERCK KGAA18.70%64 525
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD119.61%22 057
KYOWA KIRIN CO., LTD.2.02%13 715
BETTA PHARMACEUTICALS CO., LTD.63.97%6 469
YUHAN CORPORATION26.43%3 351